<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892785</url>
  </required_header>
  <id_info>
    <org_study_id>BONNOTTE PHRC N 2017</org_study_id>
    <nct_id>NCT03892785</nct_id>
  </id_info>
  <brief_title>MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial</brief_title>
  <acronym>METOGiA</acronym>
  <official_title>MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. It is&#xD;
      characterized by a granulomatous inflammation of the wall of large vessels, involving&#xD;
      especially the aorta and extra-cranial branches of the external carotid, with vascular&#xD;
      remodelling leading to ischemic manifestations such as temporal headaches, jaw claudication,&#xD;
      scalp tenderness and visual loss. Most patients with GCA also present signs of systemic&#xD;
      inflammation, including weight loss, fatigue and fever, together with an increased&#xD;
      erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level.&#xD;
&#xD;
      Glucocorticoids (GC) are the cornerstone of the treatment of GCA. They are very effective and&#xD;
      are usually given for 18-24 months to avoid relapses. Therefore, most patients develop&#xD;
      GC-related complications that cause morbidity and disability. GC sparing strategies are thus&#xD;
      required to improve the treatment of GCA.&#xD;
&#xD;
        -  A 12-month treatment with tocilizumab (TCZ) has recently been shown to be effective in&#xD;
           inducing and maintaining remission of GCA, with a dramatic GC-sparing effect. However,&#xD;
           TCZ is an expensive drug; TCZ suppresses CRP synthesis and ESR elevation so that it is&#xD;
           difficult to monitor patients; and importantly around 40% of patients relapse within 6&#xD;
           months after TCZ discontinuation, whether prescribed for 12 months or 4 months.&#xD;
&#xD;
        -  In association with 6 months of prednisone, 10 mg/week of methotrexate (MTX) for 24&#xD;
           months lowers the risk of relapse at 24 months from 84% to 45%.&#xD;
&#xD;
      Therefore, the hypothesis is that 12 months of MTX treatment (0.3 mg/Kg/week, without&#xD;
      exceeding 20 mg/week) is not inferior to 12 months of TCZ (162 mg SC/week) in term of&#xD;
      prevention of relapse at 18 months. The MTX strategy might be more cost effective than TCZ.&#xD;
&#xD;
      In the present study, it is proposed to compare MTX versus TCZ in a multicenter randomized&#xD;
      controlled trial. Moreover, the economic consequences associated with the use of MTX rather&#xD;
      than TCZ will be also assess.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients alive without relapse after initial remission or deviation from the scheduled regimen of prednisone</measure>
    <time_frame>Week 78</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone treatment</intervention_name>
    <description>tapering prednisone regimen</description>
    <arm_group_label>Methotrexate group</arm_group_label>
    <arm_group_label>Tocilizumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab treatment</intervention_name>
    <description>Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)</description>
    <arm_group_label>Tocilizumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate treatment</intervention_name>
    <description>Methotrexate subcutaneous from W0 to W51 (52 administrations).&#xD;
W0: 7.5 mg/week&#xD;
W1: 0.2 mg/Kg/week&#xD;
W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51</description>
    <arm_group_label>Methotrexate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>HAQ, SF-36, FACIT-fatigue</description>
    <arm_group_label>Methotrexate group</arm_group_label>
    <arm_group_label>Tocilizumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Additionnal blood samples for immunomonitoring</description>
    <arm_group_label>Methotrexate group</arm_group_label>
    <arm_group_label>Tocilizumab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
          -  Diagnosis of GCA, as defined by the revised GCA diagnosis criteria:44&#xD;
&#xD;
               -  Age ≥50 years at disease onset&#xD;
&#xD;
               -  AND History of erythrocyte sedimentation rate (ESR) ≥50 mm/h OR CRP≥20 mg/L (not&#xD;
                  mandatory if TAB is positive: see below)&#xD;
&#xD;
               -  AND At least one of the following:&#xD;
&#xD;
          -  unequivocal cranial symptoms of GCA (new onset headache, scalp tenderness, jaw&#xD;
             claudication, temporal artery abnormality, ischemia-related vision loss)&#xD;
&#xD;
          -  unequivocal symptoms of polymyalgia rheumatica (PMR)&#xD;
&#xD;
             o AND At least one of the following:&#xD;
&#xD;
          -  Temporal artery biopsy (TAB) compatible with the diagnosis of GCA (non-necrotizing&#xD;
             vasculitis with a predominance of mononuclear cell infiltration or granulomatous&#xD;
             inflammation, usually with multinucleated giant cells)&#xD;
&#xD;
          -  Evidence of large vessel vasculitis (aorta and/or epiaortic arteries):&#xD;
&#xD;
               -  angio-CT or angio-MRI: thickened arterial wall (≥2mm for the aorta and ≥1mm for&#xD;
                  epiaortic arteries) and/or contrast-enhanced arteries in T1-weighted sequences&#xD;
&#xD;
               -  PET scan: grade 3 tracer uptake of the arterial wall (grade 3 = arterial SUVmax&#xD;
                  superior to the SUVmax of the liver)&#xD;
&#xD;
          -  Active GCA within 6 weeks before randomization. Active GCA is defined by ESR ≥30 mm/h&#xD;
             or CRP ≥10 mg/L and at least one of the following:&#xD;
&#xD;
               -  ≥1 unequivocal cranial symptom(s) of GCA (new onset localized headache, scalp or&#xD;
                  temporal artery tenderness, ischemia-related vision loss, or otherwise&#xD;
                  unexplained mouth or jaw pain upon mastication)&#xD;
&#xD;
               -  ≥1 unequivocal symptom(s) of PMR, defined as shoulder and/or hip girdle pain&#xD;
                  associated with inflammatory stiffness&#xD;
&#xD;
               -  any other feature(s) judged by the clinical investigator to be consistent with&#xD;
                  GCA or PMR flares&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled psychotic state&#xD;
&#xD;
          -  Patient unable to give his/her consent&#xD;
&#xD;
          -  Premenopausal women (menopause is defined as amenorrhea for more than 12 consecutive&#xD;
             months)&#xD;
&#xD;
          -  Non-compliant patients&#xD;
&#xD;
          -  Weight&lt;40 Kg or &gt;100Kg&#xD;
&#xD;
          -  Patients under maintenance of justice, wardship or legal guardianship&#xD;
&#xD;
          -  History of intoxication (alcohol or medication) requiring hospitalization within 12&#xD;
             months before inclusion&#xD;
&#xD;
          -  Current chronic alcohol abuse (consumption &gt; 20g/day)&#xD;
&#xD;
          -  Recent or incoming surgery within 12 months after inclusion&#xD;
&#xD;
          -  History of stem cell or organ transplantation (except corneas performed more than 3&#xD;
             months prior inclusion)&#xD;
&#xD;
          -  Primary or secondary immunodeficiency&#xD;
&#xD;
          -  Hypersensitivity to methotrexate or tocilizumab, one of its excipients or another&#xD;
             human or murine monoclonal antibody&#xD;
&#xD;
          -  History of diverticulitis, inflammatory bowel disease, or other symptomatic&#xD;
             gastrointestinal tract condition that might predispose to bowel perforation&#xD;
&#xD;
          -  Patient refusing to sign methotrexate safety contract&#xD;
&#xD;
          -  Prior treatment with any of the following:&#xD;
&#xD;
               -  Tocilizumab or methotrexate within 12 weeks before inclusion&#xD;
&#xD;
               -  Treatment with rituximab or other anti-CD20 agent within one year before&#xD;
                  inclusion&#xD;
&#xD;
               -  Treatment with cyclophosphamide within one year before inclusion&#xD;
&#xD;
               -  Hydroxychloroquine, cyclosporine A, dapsone, azathioprine, mycophenolate mofetil&#xD;
                  or janus kinase inhibitors within 4 weeks before inclusion&#xD;
&#xD;
               -  Tumor necrosis factor inhibitors within 8 weeks (infliximab) or 2 weeks&#xD;
                  (adalimumab or etanercept) before inclusion&#xD;
&#xD;
               -  Anakinra within 1 week before inclusion&#xD;
&#xD;
          -  Long-term systemic glucocorticoid therapy ((except dermocorticoids and inhaled&#xD;
             corticoids) for other conditions than GCA or PMR&#xD;
&#xD;
          -  Patient with ≥3 prior glucocorticoid systematic therapies for another disease than GCA&#xD;
             or PMR within the 6 months before inclusion&#xD;
&#xD;
          -  Long-term treatment with sulfamethoxazole/trimethoprim (Bactrim®)&#xD;
&#xD;
          -  Live vaccine administered within 30 days before inclusion&#xD;
&#xD;
          -  Laboratory abnormalities:&#xD;
&#xD;
               -  AST or ALT &gt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  total bilirubin &gt;ULN&#xD;
&#xD;
               -  platelets&lt;100 G/L&#xD;
&#xD;
               -  leukocytes &lt;3 G/L&#xD;
&#xD;
               -  neutropenia &lt;1.5 G/L&#xD;
&#xD;
               -  lymphopenia &lt;0.5 G/L&#xD;
&#xD;
               -  haemoglobin &lt;8 g/dL (not related to GCA activity)&#xD;
&#xD;
               -  clearance of creatinine &lt;30 ml/min/1,73 m2 [CKD EPI 2009]&#xD;
&#xD;
               -  positive HBs antigen or positive HCV antibodies&#xD;
&#xD;
          -  Infections:&#xD;
&#xD;
               -  History of viral hepatitis B or C (chronic or acute)&#xD;
&#xD;
               -  HIV infection&#xD;
&#xD;
               -  Persistent infection or severe infection requiring hospitalization or intravenous&#xD;
                  antibiotics within 30 days before inclusion (antibiotic treatment tests are&#xD;
                  allowed, regardless of duration and route of administration)&#xD;
&#xD;
               -  Proven infection requiring oral antibiotics within 14 days before inclusion&#xD;
                  (antibiotic treatment tests are allowed, regardless of duration and route of&#xD;
                  administration)&#xD;
&#xD;
               -  Prior history of histoplasmosis or listeriosis&#xD;
&#xD;
               -  Active tuberculosis&#xD;
&#xD;
               -  Latent tuberculosis (diagnosis based on history of non-treated contact, opacity&#xD;
                  with a diameter greater than 1 cm on chest radiography, or positive in vitro&#xD;
                  test: Quantiferon Gold® or T-Spot-TB®).&#xD;
&#xD;
        NB: a history of tuberculosis for which treatment is over and was correctly precribed&#xD;
        regarding usual recommendations is not an exclusion criteria, whatever the results of&#xD;
        Quantiferon Gold® or T-Spot-TB® tests.&#xD;
&#xD;
        - Unstable or poorly controlled, acute or chronic disease, not due to GCA, and which&#xD;
        contraindicates tocilizumab or methotrexate:&#xD;
&#xD;
          -  Recurrent infections, unstable ischemic heart disease, renal failure (creatinine&#xD;
             clearance &lt;30 ml/min/1,73 m2 [CKD EPI 2009]), liver failure, current liver disease,&#xD;
             heart failure ≥ NYHA stage III/IV, respiratory failure&#xD;
&#xD;
          -  Neoplasia &lt; 5 years, (except for in situ cervical cancer and skin carcinoma, except&#xD;
             melanoma, with R0 resection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernard BONNOTTE</last_name>
    <phone>+33 3 80 29 34 32</phone>
    <phone_ext>+33</phone_ext>
    <email>Bernard.bonnotte@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard BONNOTTE</last_name>
      <phone>3 80 29 34 32</phone>
      <phone_ext>+33</phone_ext>
      <email>bernard.bonnotte@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

